Telehealth firm Hims & Hers Health said on Tuesday it plans to sell Eli Lilly's weight-loss drug, as it widens its offerings ...

A bride-to-be is questioning her friendship with one of her closest friends after she reacted negatively to their weddings ...

HIMS has experienced similar dramatic drops before. During the 2022 inflation surge, the stock fell 87%, and in 2020, it ...

Hims & Hers Health (NYSE: HIMS) stock labored mightily on Wednesday, but in the end, it couldn't top the benchmark S&P 500 index. Investor excitement about news of a fresh product launch the previous ...

The telehealth-consultation platform said it plans to continue expanding its weight loss offerings.

The Justice Department under Attorney General Pam Bondi faces naby lawsuits over deportations and other Trump policies even ...

Hims & Hers Health shares jumped Tuesday as the company added Eli Lilly’s weight-loss drug Zepbound and diabetes treatment Mounjaro to its telehealth platform.

John Stamos celebrated his son Billy's 7th birthday — and his wife Caitlin McHugh who welcomed him into the world — with a ...

Zepbound is made by drugmaker Eli Lilly. While Hims & Hers offers it for $1,899 per month, Lilly said the price on its own LillyDirect platform starts at $349 for self-paying customers. With insurance ...

Jefferies analyst Glen Santangelo raised the firm’s price target on Hims & Hers to $25 from $21 and keeps a Hold rating on the shares. A ...

Truist analyst Jailendra Singh lowered the firm’s price target on Hims & Hers to $33 from $39 and keeps a Hold rating on the shares as part ...

Shares of the health and wellness platform operator skyrocketed more than 670% between Jan. 1, 2024, and Feb. 19, 2025. However, this sizzling momentum came to a screeching halt in recent weeks. Hims ...